HK1131389A1 - Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy - Google Patents

Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy

Info

Publication number
HK1131389A1
HK1131389A1 HK09111033.7A HK09111033A HK1131389A1 HK 1131389 A1 HK1131389 A1 HK 1131389A1 HK 09111033 A HK09111033 A HK 09111033A HK 1131389 A1 HK1131389 A1 HK 1131389A1
Authority
HK
Hong Kong
Prior art keywords
thiazolo
pyrimidin
disubstituted
therapy
derivatives
Prior art date
Application number
HK09111033.7A
Other languages
English (en)
Inventor
Rolf Johansson
Sofia Karlstroem
Annika Kers
Gunnar Nordvall
Tobias Rein
Can Slivo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39230456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1131389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1131389A1 publication Critical patent/HK1131389A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
HK09111033.7A 2006-09-29 2009-11-26 Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy HK1131389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82746006P 2006-09-29 2006-09-29
US82812506P 2006-10-04 2006-10-04
PCT/SE2007/000857 WO2008039138A1 (en) 2006-09-29 2007-09-27 Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy

Publications (1)

Publication Number Publication Date
HK1131389A1 true HK1131389A1 (en) 2010-01-22

Family

ID=39230456

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09111033.7A HK1131389A1 (en) 2006-09-29 2009-11-26 Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy

Country Status (22)

Country Link
US (2) US7960395B2 (xx)
EP (1) EP2069364B1 (xx)
JP (1) JP5422386B2 (xx)
KR (1) KR101345085B1 (xx)
AR (1) AR063023A1 (xx)
AT (1) ATE537177T1 (xx)
AU (1) AU2007300748B2 (xx)
BR (1) BRPI0717109A2 (xx)
CA (1) CA2664789A1 (xx)
CL (1) CL2007002813A1 (xx)
CO (1) CO6150165A2 (xx)
ES (1) ES2377469T3 (xx)
HK (1) HK1131389A1 (xx)
IL (1) IL197293A0 (xx)
MX (1) MX2009003005A (xx)
NO (1) NO20091579L (xx)
NZ (1) NZ576520A (xx)
PE (1) PE20080973A1 (xx)
RU (1) RU2441012C2 (xx)
TW (1) TW200820973A (xx)
UY (1) UY30612A1 (xx)
WO (1) WO2008039138A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
ES2642805T3 (es) 2013-03-12 2017-11-20 Eisai R&D Management Co., Ltd. Sal de un derivado del ácido pirrolidín-3-ilacético y cristales de esta
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
BRPI0415050A (pt) * 2003-10-07 2006-11-28 Astrazeneca Ab composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (xx) 2005-04-06 2010-05-25 Астразенека Аб 5-ЗАМІЩЕНІ ПОХІДНІ 7-АМІНО-$1,3]ТІАЗОЛО$4,5-d]ПІРИМІДИНУ$5-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 7-АМИНО-$1,3]ТИАЗОЛО$4,5-d]ПИРИМИДИНА

Also Published As

Publication number Publication date
US20110105537A1 (en) 2011-05-05
IL197293A0 (en) 2009-12-24
JP5422386B2 (ja) 2014-02-19
KR20090057069A (ko) 2009-06-03
CO6150165A2 (es) 2010-04-20
CA2664789A1 (en) 2008-04-03
AR063023A1 (es) 2008-12-23
EP2069364A4 (en) 2010-03-24
NZ576520A (en) 2011-08-26
NO20091579L (no) 2009-04-21
BRPI0717109A2 (pt) 2013-10-08
KR101345085B1 (ko) 2013-12-31
EP2069364B1 (en) 2011-12-14
MX2009003005A (es) 2009-04-01
TW200820973A (en) 2008-05-16
RU2441012C2 (ru) 2012-01-27
WO2008039138A8 (en) 2009-03-19
US7960395B2 (en) 2011-06-14
CL2007002813A1 (es) 2008-04-04
US20080318981A1 (en) 2008-12-25
ES2377469T3 (es) 2012-03-27
AU2007300748B2 (en) 2011-09-08
AU2007300748A1 (en) 2008-04-03
PE20080973A1 (es) 2008-10-02
WO2008039138A1 (en) 2008-04-03
EP2069364A1 (en) 2009-06-17
RU2009109100A (ru) 2010-11-10
UY30612A1 (es) 2008-05-02
JP2010504962A (ja) 2010-02-18
ATE537177T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
IL185913A0 (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives
IL183182A0 (en) Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
IL180757A0 (en) Imidazo[4,5-d] pyrimidines, their uses and methods of preparation
PL2217578T3 (pl) Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanie
IL189578A0 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
ZA200705123B (en) Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
IL198273A0 (en) Substituted 2,3-dihydroimidazo[1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
IL183512A (en) Annals of 5-Amino-2-Oxo-Thiazolo [d-5,4] Pyrimidine-3 (or 2) Ill- Tetrahydroporan, Containing and Using Pharmaceutical Preparations
IL195017A0 (en) Pyrazolo [3,4-d]pyrimidine derivatives useful to treat respiratory disorders
IL201977A (en) 6- (Pyrrolidine-3-Yl) -Pyrazolo [4,3- d] Pyrimidine-4-Ones, Pharmaceuticals Including Them and Their Use in the Preparation of Medicines to Treat Diseases
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
ZA200708524B (en) Process for preparing pyrido[2,3-D]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one derivatives
IL197298A0 (en) Novel 5,7-disubstituted (1,3)thiazolo [4,5-d]pyrimidin-2 (3h)-amine derivatives and their use in therapy
MX2009002995A (es) Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
SI1635839T1 (sl) Benzo(4,5)tieno(2,3-d)pirimidin-4-oni in njihova uporaba pri terapiji
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
IL187900A0 (en) Derivatives of pyrido[2,3-d] pyrimidine, the preparation thereof, and the therapeutic application of the same
HK1131389A1 (en) Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy
IL195949A0 (en) Use of derivatives of imidazo[1,2-a]pyridine-2-carboxamides in therapeutics
ZA200901476B (en) Novel 5, 7-disubstituted [1,3] thiazolo [4, 5-D] pyrimidin-2 (3H)-one derivatives and their use in therapy
IL206669A0 (en) 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
GB2453116B (en) Uses of 2-[piperidinyl]methy1-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect
IL183705A (en) Macrocyclic quinazole derivatives and their use as mtki

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160927